SynthesisDiabetologia2021
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis.
Synthesis in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 8 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.Therapeutic innovation & regulatory science · 2024 · on this mapPooled it
- Associations of diabetes, hypertension and obesity with COVID-19 mortality: a systematic review and meta-analysis.BMJ global health · 2023Pooled it
- Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis.Diabetologia · 2023Pooled it
- Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.Metabolism: clinical and experimental · 2022Pooled it
- Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews.Frontiers in public health · 2022Pooled it
- Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- [Quality of systematic reviews of COVID-19 in people with diabetes: A systematic review].Enfermeria clinicaPooled it
- Quality of systematic reviews of COVID-19 in people with diabetes: A systematic review.Enfermeria clinicaPooled it
- Impact of diabetes on COVID-19 prognosis beyond comorbidity burden: the CORONADO initiative.Diabetologia · 2022Trial
- Article
- Outpatient Health Service Utilization Among Adults with Diabetes, Hypertension and Cardiovascular Disease During the COVID-19 Pandemic - Results of Population-Based Surveys in Germany from 2019 to 2021.Journal of multidisciplinary healthcare · 2024Article
- Increased risk of poor clinical outcome in COVID-19 patients with diabetes mellitus and in-hospital mortality predictors: A retrospective cohort from a tertiary hospital in Indonesia.Endocrinology, diabetes & metabolism · 2023Article
- Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19).Diabetology & metabolic syndrome · 2023Article
- Glucose control in the early phase of hospitalization is associated with severe prognosis in coronavirus disease 2019 (COVID-19) patients with diabetes in Japan.Diabetology international · 2023Article
- Review
- Long-term multiple metabolic abnormalities among healthy and high-risk people following nonsevere COVID-19.Scientific reports · 2023Article
- Methodological quality and reporting quality of COVID-19 living systematic review: a cross-sectional study.BMC medical research methodology · 2023Article
- Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study.Nutrition & diabetes · 2023Article
- Acupoint stimulation for long COVID: A promising intervention:.World journal of acupuncture-moxibustion · 2023Review
- COVID-19 vaccination status among people with selected citizenships: results of the study GEDA Fokus.Journal of health monitoring · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
aims/hypothesisDiabetes has been identified as a risk factor for poor prognosis of coronavirus disease-2019 (COVID-19). The aim of this study is to identify high-risk phenotypes of diabetes associated with COVID-19 severity and death.
methodsThis is the first edition of a living systematic review and meta-analysis on observational studies investigating phenotypes in individuals with diabetes and COVID-19-related death and severity. Four different databases were searched up to 10 October 2020. We used a random effects meta-analysis to calculate summary relative risks (SRR) with 95% CI. The certainty of evidence was evaluated by the GRADE tool.
resultsA total of 22 articles, including 17,687 individuals, met our inclusion criteria. For COVID-19-related death among individuals with diabetes and COVID-19, there was high to moderate certainty of evidence for associations (SRR [95% CI]) between male sex (1.28 [1.02, 1.61], n = 10 studies), older age (>65 years: 3.49 [1.82, 6.69], n = 6 studies), pre-existing comorbidities (cardiovascular disease: 1.56 [1.09, 2.24], n = 8 studies; chronic kidney disease: 1.93 [1.28, 2.90], n = 6 studies; chronic obstructive pulmonary disease: 1.40 [1.21, 1.62], n = 5 studies), diabetes treatment (insulin use: 1.75 [1.01, 3.03], n = 5 studies; metformin use: 0.50 [0.28, 0.90], n = 4 studies) and blood glucose at admission (≥11 mmol/l: 8.60 [2.25, 32.83], n = 2 studies). Similar, but generally weaker and less precise associations were observed between risk phenotypes of diabetes and severity of COVID-19. CONCLUSIONS/
interpretationIndividuals with a more severe course of diabetes have a poorer prognosis of COVID-19 compared with individuals with a milder course of disease. To further strengthen the evidence, more studies on this topic that account for potential confounders are warranted. REGISTRATION: PROSPERO registration ID CRD42020193692.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.